TY - JOUR
TI - Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)
AU - Tsironis, G.
AU - Koutsoukos, K.
AU - Athanasakis, K.
AU - Tsiara, A.
AU - Tzannis, K.
AU - Gerolympou, M.
AU - Visvikis, A.
AU - Oikonomopoulos, G.
AU - Kollia, A.
AU - Giannopoulou, E.
AU - Dimitra, M.
AU - Kostouros, E.
AU - Papatsoris, A.
AU - Dellis, A.
AU - Stravodimos, K.
AU - Varkarakis, I.
AU - Samantas, E.
AU - Aravantinos, G.
AU - Kentepozidis, N.
AU - Christodoulou, C.
AU - Bozionelou, V.
AU - Dimopoulos, M.A.
AU - Bamias, A.
JO - Expert Review of Pharmacoeconomics and Outcomes Research
PY - 2019
VL - 19
TODO - 4
SP - 491-501
PB - Taylor and Francis Ltd.
SN - 1473-7167, 1744-8379
TODO - 10.1080/14737167.2019.1546121
TODO - axitinib;  everolimus;  nivolumab;  pazopanib;  sorafenib;  sunitinib;  antineoplastic agent;  pazopanib;  pyrimidine derivative;  sulfonamide;  sunitinib, adult;  adverse outcome;  alopecia;  anemia;  Article;  cancer survival;  cardiotoxicity;  controlled study;  cost benefit analysis;  cost effectiveness analysis;  diarrhea;  drug cost;  drug efficacy;  drug safety;  fatigue;  female;  hair discoloration;  hand disease;  human;  hypertension;  hypothyroidism;  kidney metastasis;  liver toxicity;  major clinical study;  male;  middle aged;  mucosa inflammation;  multicenter study;  nausea and vomiting;  nephrotoxicity;  neurotoxicity;  neutropenia;  outcome assessment;  overall survival;  peripheral edema;  practice guideline;  progression free survival;  retrospective study;  skin manifestation;  skin toxicity;  survival rate;  survival time;  taste disorder;  thrombocytopenia;  thrombosis;  aged;  clinical practice;  clinical trial;  disease free survival;  economics;  follow up;  Greece;  kidney tumor;  metastasis;  molecularly targeted therapy;  pharmacoeconomics;  procedures;  renal cell carcinoma;  statistics and numerical data;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antineoplastic Agents;  Carcinoma, Renal Cell;  Cost-Benefit Analysis;  Disease-Free Survival;  Economics, Pharmaceutical;  Female;  Follow-Up Studies;  Greece;  Humans;  Kidney Neoplasms;  Male;  Middle Aged;  Molecular Targeted Therapy;  Neoplasm Metastasis;  Practice Patterns, Physicians';  Pyrimidines;  Retrospective Studies;  Sulfonamides;  Sunitinib;  Survival Rate
TODO - Background:Metastatic RCC (mRCC) treatment has been revolutionized with 11 approved targeted agents. We report patterns of practice, outcomes and pharmacoeconomic analyses after the introduction of targeted therapy. Patients and methods: CRISIS was a retrospective multicenter study of mRCCpatients who received targeted therapy. Results were related to the start of 1st-line therapy, with a cut off at 1 January 2011 in order to depict the impact of increased availability of effective options. Results: 164 patients, were included. 70.1% and 44.5% received 2nd and 3rd-line therapy, respectively. More patients were treated in 2nd-line after 1 January 2011. After a median follow-up of 55.1 months, median progression-free (PFS) and overall survival (OS) were 10.7 (95% confidence intervals [CI]: 8.3–13.7), 7.3 (95% CI: 5.1–8.6), 5.8 (95% CI: 3.8–7.8) and 34 (95% CI: 28.5–39.8), 22.4 (95% CI: 16–32.1), 18.3 (95% CI: 12.4–26.4) months for first, second and third line, respectively. Efficacy of sunitinib and pazopanib in 1st-line were similar. The mean total cost/patient was 35,012.2 Euros (standard deviation [SD]: 28,971.5). Conclusions: Our study confirms previous real-world data suggesting that continuing advances in the treatment of mRCC produce favorable outcomes in everyday practice. Pharmacoeconomic analyses are important for cost-effective utilization of emerging novel therapies. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
ER -